Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
Treatment with ETI significantly decreased antibiotic utilization and the prevalence of gram-negative organisms. Although fewer antibiotics were used, antibiotic resistance remained unchanged or even increased post-ETI due largely to the greater persistence of resistant organisms.
Authors
- Charles R. Esther (ORCID: https://orcid.org/0000-0002-8081-2986)
- Jo Billings (ORCID: https://orcid.org/0000-0003-1238-2440)
- William S. Wilson (ORCID: https://orcid.org/0000-0001-5837-066X)
- Charissa W. Kam (ORCID: https://orcid.org/0000-0003-3419-2613)
- Hilary McGowan
- Rebecca McDevitt
- Cameron J. McKinzie (ORCID: https://orcid.org/0000-0003-1401-5628)
- C. Williams
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/ppul.71038
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52